Sanne P. Smeekens

Sanne P. Smeekens

Auto-generated profile, based on publicly available information

Sanne P. Smeekens

Department of Human Genetics, Radboud University Medical Center , Nijmegen , The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
RHRob ter Horst
Rob ter Horst
MJmartin Jaeger
martin Jaeger
LWLisa van de Wijer
Lisa van de Wijer
WHWouter A van der Heijden
Wouter A van der Heijden
AJAnna M W Janssen
Anna M W Janssen
LJLeo A.B. Joosten
Leo A.B. Joosten
Different components of the immune response show large variability between individuals, but they also vary within the same individual because of host and environmental factors. In this study, we report an extensive analysis of the immune characteristics of 56 individuals over four timepoints in 1 single year as part of the Human Functional Genomics Project. We characterized 102 cell subsets using flow cytometry; quantified production of eight cytokines and two chemokines in response to 20 metabolic, bacterial, fungal, and viral stimuli; and measured circulating markers of inflammation. Taking advantage of the longitudinal sampling, both seasonal and nonseasonal sources of variability were studied. The circulating markers of inflammation IL-18, IL-18 binding protein, and resistin displayed clear seasonal variability, whereas the strongest effect was observed for α-1 antitrypsin. Cytokine production capacity also showed strong seasonal changes, especially after stimulation with the influenza virus, Borrelia burgdorferi, and Escherichia coli. Furthermore, we observed moderate seasonality effects on immune cell counts, especially in several CD4+/CD8+ T cell subpopulations. Age of the volunteers was an important factor influencing IFN-γ and IL-22 production, which matched the strong impact of age on several T cell subsets. Finally, on average, genetics accounted for almost 50% of the interindividual variance not already explained by age, sex, and body mass index, although this varies strongly for different parameters. In conclusion, seasonality is an important environmental factor that influences immune responses, in addition to specific genetic and nongenetic host factors, and this may well explain the seasonal variation in the incidence and severity of immune-mediated diseases.

1 January 2021 in Cytokine
Verified
Journal Article
Closed access
DGDennis M. de Graaf
Dennis M. de Graaf
RMRalph J.A. Maas
Ralph J.A. Maas
SSSanne P. Smeekens
Sanne P. Smeekens
EEElan Eisenmesser
Elan Eisenmesser
JRJasmina S. Redzic
Jasmina S. Redzic
FVFrank van de Veerdonk
Frank van de Veerdonk

6 October 2016 in Nature Medicine
Verified
Journal Article
Open access
YLYang Li
Yang Li
MOMarije Oosting
Marije Oosting
PDPatrick Deelen
Patrick Deelen
IRIsis Ricaño-Ponce
Isis Ricaño-Ponce
SSSanne Smeekens
Sanne Smeekens
MNMihai G. Netea
Mihai G. Netea
Nat. Med.; doi:10.1038/nm.4139; corrected online 28 July 2016 In the version of this article initially published online, the url in the Online database section of the Methods was incorrect. The original version included the url http://www.bbmri.nl/molgenis/500FG. The correct url is http://hfgp.bbmri.nl/. The error has been corrected for the print, PDF and HTML versions of this article.

23 May 2024 in Prenatal Diagnosis
Verified
Journal Article
Open access
SSSanne P. Smeekens
Sanne P. Smeekens
MLMaike. Leferink
Maike. Leferink
HYHelger G. Yntema
Helger G. Yntema
EKErik‐Jan Kamsteeg
Erik‐Jan Kamsteeg
Objective: Maternal cell contamination (MCC) poses a risk for misdiagnosis in prenatal genetic testing, and is examined in accredited diagnostic laboratories However, the awareness of possible MCC in perinatal/postnatal genetic testing, mainly of umbilical cord blood (CB), is lower.Method: We investigated the rate of MCC in DNA from both umbilical CB samples and umbilical cord samples that were sent to our diagnostic laboratory for diagnostic testing between 1995 and 2021 (n = 236).Results: MCC was detected in 4% of umbilical CB samples, and in one umbilical cord sample. Particularly tests enriching for a specific variant are very sensitive for low amounts of MCC, as we emphasize here with a false positive diagnosis of myotonic dystrophy type 1 in a newborn.Conclusions: Overall, with appropriate collection and use, umbilical CB and umbilical cord samples are suitable for genetic testing based on the low rates of MCC and misdiagnosis. These findings do however underline the importance of routine MCC testing in umbilical CB samples and umbilical cord samples for both requesting clinicians and diagnostic genetic laboratories.

12 June 2024 in Clinical Chemistry
Verified
Journal Article
Open access
SSSanne P Smeekens
Sanne P Smeekens
RTRaoul Timmermans
Raoul Timmermans
DWDineke Westra
Dineke Westra
CGChristian Gilissen
Christian Gilissen
BFBrigitte H W Faas
Brigitte H W Faas
Background: Maternal cell contamination (MCC) in prenatal samples poses a risk for misdiagnosis, and therefore, testing for contamination is necessary during genetic analysis of prenatal specimens. MCC testing is currently performed as a method separate from the diagnostic method. With the increasing application of whole exome sequencing (WES) in prenatal diagnosis, we sought to develop a method to estimate the level of contamination from WES data, aiming to eliminate the need for a separate MCC test. Methods: To investigate the impact of MCC on the distribution of the variant allele fraction in WES data, contamination was both simulated in silico and artificially induced. Subsequently, a bioinformatic WES contamination method was developed and validated by comparing its performance to that of the gold standard (short tandem repeat [STR]) MCC test, validated for detecting ≥5% contamination. Finally, post-implementation performance was monitored for a 15-month period. Results: During validation, 270 prenatal samples underwent analysis with both WES and the gold standard test. In 259 samples, the results were concordant (248 not contaminated, 11 contaminated with both tests). In 11 samples, contamination was only detected in WES data (2 of which contained ≥5% contamination with WES, which is above the detection limit of the gold standard test). The data of the post-implementation evaluation on 361 samples, of which 68 were contaminated, were in line with the validation data. Conclusions: Contamination can reliably be detected in WES data, rendering a separate contamination test unnecessary for the majority of samples.

3 November 2026 in Movement Disorders
Verified
Journal Article
Open access
TBTeodora Barbarii
Teodora Barbarii
SSSanne P. Smeekens
Sanne P. Smeekens
MPMaartje Pennings
Maartje Pennings
GAGaluh Astuti
Galuh Astuti
LVLisenka E.L.M. Vissers
Lisenka E.L.M. Vissers
EKErik‐Jan Kamsteeg
Erik‐Jan Kamsteeg
Background: Molecular testing for genetic movement disorders (MDs) increasingly relies on exome‐ or genome‐based virtual gene panels. In the absence of consensus guidelines, MD panel design remains heterogeneous across laboratories, with international variation in panel configuration and gene content. Objective: The aim of this work was to develop a reproducible framework for a unified MD panel design, generate a comprehensive, curated gene‐phenotype dataset, and evaluate clinical utility via targeted exome reanalysis. Methods: Candidate genes were extracted from multiple resources and assessed using predefined criteria for panel inclusion and gene‐disease validity. Genes were tiered as Green, Amber, or Red based on evidence strength. Phenotypic spectrum and age at onset were assessed for Green genes based on published literature. Newly added Green and Amber genes were investigated in 4,046 exomes from previously undiagnosed MD cases. Results: Among 2,090 extracted genes, 640 were selected. The final panel included 537 Green, 36 Amber, and 67 Red genes, expanding the prior panel by 283 genes and removing 42. Across Green genes, only 17% were linked to a single MD feature, whereas the remainder associated up to eight. Age‐at‐onset data indicated both pediatric and adult presentations in 43% of genes. Targeted exome reanalysis using a 220‐gene list identified 37 clinically relevant variants across 28 genes, resolving 16 cases and increasing diagnostic yield by 0.4%. Conclusions: This study offers a systematic framework for designing a unified MD panel by integrating evidence from multiple sources and accounting for phenotypic and age heterogeneity. Targeted reanalysis yielded actionable diagnoses, confirming its benefit in routine clinical practice. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.